In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement for combination. Under the stock-for-stock agreement, GEDiCube will become a wholly-owned subsidiary of Renovaro. The company’s CEO, Dr. Mark Dybul, MD, recently sent a letter to Renovaro shareholders to provide an update on the union – sharing the vision of the combination and expressing appreciation for their ongoing support and investment (https://ibn.fm/yFhPk).
“We believe GEDiCube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” press releases from the combination announcement quote Dr. Dybul as saying (https://ibn.fm/V1UyG). “The combined company will have independent operating divisions that will allow each technology to move as quickly as possible to commercialization while the collaboration between divisions will aim to drive new advances in both AI and medicine.”
According to Dr. Dybul, the AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the precision medicine market, which Renovaro is positioned to capture a substantial share of the largely untapped market.
The immunotherapy division plans to start Phase 1/2 trials of its lead asset in the second half of 2024, a breakthrough approach Dr. Dybul believes could lead to emergency use authorization as soon as the end of 2027 – following the results of a Phase 2 clinical trial that will transform treatment for cancers with low survival rates, like pancreatic cancer.
The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies. GEDiCube’s award-winning AI technology has already shown the ability to detect lung cancer early with 95% accuracy by analyzing complex molecular data. The company’s proprietary platform searches for patterns across genomics, epigenomics, transcriptomics, and other omics layers to identify informative biomarkers for over 12 cancers thus far. The company will rebrand as Renovaro.AI as outlined in the combination agreement.
Renovaro’s strength is its advanced immunotherapy platform focused initially on some of the deadliest solid tumor cancers that have seen only marginal improvement in survival rates over the past several decades. The company’s patented approach modifies allogeneic dendritic cells to stimulate anti-tumor immunity specific to a patient’s genetic profile. Remarkably, Renovaro’s personalized vaccine technology has shown an 80-90% reduction in tumor size, and the company expects to start human trials during the second half of 2024.
In his letter to the company’s shareholders, Dr. Dybul underlines that, like any cutting-edge company, there will be challenges ahead – but that the need has never been greater for transformative solutions that the combination of Renovaro and GEDiCube can provide. Dr. Dybul believes that there is a vision, technology, and talent that can transform how cancer is detected and managed early on. The companies have an opportunity and responsibility to fundamentally transform the lives of patients and families across the globe and help define the future of medicine.
For more information, visit the company’s website at www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…
Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months…